Shilpa Medicare has informed that the US FDA has issued an Establishment Inspection Report (EIR) for the Company’s formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017. FDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued. They wish to confirm that earlier status of their formulation unit is maintained.
The above information is a part of company’s filings submitted to BSE.
